Noriko Yanagitani
The Cancer Institute Hospital · 286 works · 7,883 citations · h-index 45
Top works
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
- Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
- Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
- Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy
- Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer
- Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine Positron Emission Tomography in Combination With 18F-Fluorodeoxyglucose in Sarcoidosis Patients
- Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
- EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer
- 1373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
- Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer
- l ‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms
- Evaluation of a whole‐genome amplification method based on adaptor‐ligation PCR of randomly sheared genomic DNA
- P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
- Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk
- Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor
- Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study
- Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility.
- Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
- Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
- The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models